Integral Health Asset Management LLC Has $16.16 Million Holdings in Elevance Health, Inc. $ELV

Integral Health Asset Management LLC lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 16.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,000 shares of the company’s stock after selling 10,000 shares during the quarter. Elevance Health comprises 1.1% of Integral Health Asset Management LLC’s portfolio, making the stock its 23rd largest holding. Integral Health Asset Management LLC’s holdings in Elevance Health were worth $16,156,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ELV. Vanguard Group Inc. raised its holdings in Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after acquiring an additional 141,747 shares during the period. Wellington Management Group LLP grew its position in shares of Elevance Health by 4.8% in the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after purchasing an additional 303,099 shares during the last quarter. Sanders Capital LLC increased its position in Elevance Health by 24.7% in the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after buying an additional 1,152,440 shares during the period. Artisan Partners Limited Partnership increased its position in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after buying an additional 901,626 shares during the period. Finally, First Eagle Investment Management LLC lifted its holdings in shares of Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after buying an additional 798,457 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

Shares of NYSE:ELV opened at $291.69 on Friday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The firm has a market cap of $64.38 billion, a PE ratio of 11.61, a price-to-earnings-growth ratio of 1.59 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The business has a fifty day moving average of $338.25 and a 200-day moving average of $334.11.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.39%.

Wall Street Analyst Weigh In

ELV has been the topic of several research analyst reports. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Mizuho decreased their price objective on Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a report on Wednesday. Barclays reduced their target price on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Finally, Leerink Partners boosted their price target on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research note on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.